Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(15):1120-1121; doi:10.1093/jnci/93.15.1120
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Thor, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thor, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 15, 1120-1121, August 1, 2001
© 2001 Oxford University Press

EDITORIAL

Are Patterns of HER-2/neu Amplification and Expression Among Primary Tumors and Regional Metastases Indicative of Those in Distant Metastases and Predictive of Herceptin Response?

Ann Thor

Correspondence to: Ann Thor, M.D., University of Oklahoma College of Medicine, 940 Stanton L. Young Blvd., BMSB 451, Oklahoma City, OK 73104.

HER-2/neu (ERB-B2), a member of the receptor tyrosine kinase superfamily, is altered by gene amplification and/or protein overexpression in a wide variety of human epithelial malignancies. Such alterations activate signaling systems that promote cell growth, angiogenesis, cancer metastases, and other procarcinogenic pathways (1). These HER-2 abnormalities are found in approximately one third of breast cancers. HER-2 "status" is a loose and suboptimal term that is commonly used to describe the degree of HER-2 gene amplification and/or the extent of Her-2 protein overexpression. HER-2 status has been used as a marker for breast cancer prognosis (in addition to the classic markers lymph node status, tumor size, type and grade, hormone receptor status, and proliferation rate), because, in the majority of cases, HER-2 alterations independently portend a worse outcome. In addition, associations have been found between the degree of HER-2 expression or gene . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
J. A. Menendez, I. Mehmi, and R. Lupu
Trastuzumab in Combination With Heregulin-Activated Her-2 (erbB-2) Triggers a Receptor-Enhanced Chemosensitivity Effect in the Absence of Her-2 Overexpression
J. Clin. Oncol., August 10, 2006; 24(23): 3735 - 3746.
[Abstract] [Full Text] [PDF]